A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
Status:
Completed
Trial end date:
2009-03-20
Target enrollment:
Participant gender:
Summary
GSK598809 is being developed as an innovative treatment for substance dependence and
potentially other compulsive behavioral disorders. This study will asses the effects of a
single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male
volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or
GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of
at least seven days between each session.